drugset / Trial / NCT00653341

Effect of Insulin Glargine in Insulin Naïve Subjects With Type 2 Diabetes on Oral Hypoglycemic Agent(s)

NCT00653341

Phase 3 Completed 764 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to compare the percentage of subjects who reach the target HbA1c level (\< or = 7.0% at endpoint) and do not experience symptomatic nocturnal hypoglycemia during treatment with insulin glargine or NPH human insulin.

Timeline

Start
2000-01
Primary completion
2001-10
Completion
2001-10

Drugs

EvaluationDrugModalityDoseRoute
Subject INSULIN SUSP ISOPHANE RECOMBINANT HUMAN Protein / enzyme biologic
Subject insulin glargine Protein / enzyme biologic